Ligand Pharmaceuticals (LGND) announces better-than-expected results in first-quarter 2023. Management raises 2023 financial outlook.
OmniAb, Inc. (Nasdaq: OABI) will report financial results for the three months ended March 31, 2023 before the open of the U.S. financial markets on Thursday, May 11, 2023 and will hold a conference call...
OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in five upcoming investor conferences in May.
Investors need to pay close attention to OmniAb (OABI) stock based on the movements in the options market lately.
OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2022, and provided operating and partner program updates.
OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and 12 months ended December 31, 2022 after the close of the U.S. financial markets on Thursday, March 30, 2023 and will hold a...
Ligand Pharmaceuticals (LGND) announces better-than-expected results in fourth-quarter 2022. Stock is up in the after-market hours in response to the news. Management raises 2023 financial outlook.
OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in three upcoming investor conferences.
OmniAb, Inc. (NASDAQ: OABI) reported financial results for the three and nine months ended September 30, 2022 and provided operating and program updates. OmniAb was part of Ligand Pharmaceuticals Incorporated...
Ligand (LGND) reports mixed third-quarter 2022 numbers, beating sales estimates but missing out on earnings. Share price rises as management lifts financial guidance for the year.